Cancer Leadership Council
Home  |  Sitemap  |  Contact Info
About CLCWhat's NewPolicy IssuesParticipants' Login

Clinical Trials—Medicare  |  Clinical Trials—Private Insurance  |  Medicare Payment
FDA  |  Cancer Research  |  Stem Cell Research  |  Privacy  |  Other
Policy Issues

PDF versionPrinter-friendly

CLC Commends Development of NCCN Compendium
(November 18, 2005)

November 18, 2005

William T. McGivney, Ph.D.
Chief Executive Officer
National Comprehensive Cancer Network
500 Old York Road - Suite 250
Jenkintown, PA 19046

Dear Dr. McGivney:

Thank you for your recent presentation to the Cancer Leadership Council (CLC) regarding development of a compendium of drug usage by the National Comprehensive Cancer Network (NCCN). The accumulation of cancer care expertise among the NCCN institutions represents a valuable resource for the cancer community, as well as for policy makers and third-party payers, and we commend NCCN for its efforts to develop this new compendium.

As you know, drug compendia like that being developed by NCCN play an important role in the determinations to cover off-label uses of by Medicare, Medicaid and other payers under §§1861(t)(2)(B) and 1927(k)(2) of the Social Security Act. While the statute specifies the compendia to be used for this purpose, authority is also provided for the Secretary of Health and Human Services (HHS) to designate additional compendia to support coverage of off-label uses of drugs utilized in cancer treatment.

The use of compendia to identify appropriate off-label uses of cancer drugs is a well-established and necessary policy; indeed, many of the members of the CLC participated in the legislative effort to establish the compendia-based system in 1991-93. We believe that the system will work best if it is flexible and responsive enough to include qualified compendia beyond those specifically mentioned in the statute. Accordingly, at the appropriate juncture, we encourage the Secretary to consider favorably the qualifications of the NCCN compendium to act as a reference for off-label coverage decisions by Medicare and Medicaid.

We look forward to hearing about your progress in developing the compendium and in securing its use for coverage purposes.


Cancer Leadership Council

American Cancer Society
American Psychosocial Oncology Society
American Society of Clinical Oncology
American Society for Therapeutic
Radiology & Oncology
C3: Colorectal Cancer Coalition
Cancer Care, Inc.
Cancer Research and Prevention Foundation
The Children's Cause for Cancer Advocacy
Fertile Hope
International Myeloma Foundation
Kidney Cancer Association
Lance Armstrong Foundation
The Leukemia & Lymphoma Society
The Lung Cancer Alliance
Lymphoma Research Foundation
Multiple Myeloma Research Foundation
National Coalition for Cancer Survivorship
National Patient Advocate Foundation
National Prostate Cancer Coalition
North American Brain Tumor Coalition
Ovarian Cancer National Alliance
Pancreatic Cancer Action Network
Sarcoma Foundation of America
Y-ME National Breast Cancer Organization

Back to Other Index



About CLC  |  What's New  |  Policy Issues  |  Participants' Login
Home  |  Sitemap  |  Contact Info

Copyright © 2001-2002 Cancer Leadership Council. All rights reserved.
Please send comments and suggestions to